Infrared-A (IR-A) Mediated Hyperthermia in the Treatment of Scleroderma-Associated Raynaud’s Phenomenon

1. Efficacy of Infrared-A Mediated Hyperthermia in Scleroderma-Associated Raynaud’s Phenomenon

Clinical research confirms that Whole-Body hyperthermia with wIRA radiation is an *effective method* for the treatment of *Raynaud’s Phenomenon (RP)* associated with *Systemic Sclerosis (Scleroderma)* [1]. By utilizing *Mild WB Hyperthermia (Mild wIR-A hyperthermia)*, the treatment targets the *vasoconstrictive symptoms* of RP, contributing to improved *microcirculation* and the management of the autoimmune skin and organ condition [2, 3]. These treatments represent an important *adjuvant therapy* in the complex management of scleroderma.

Mechanisms and Clinical Evidence

Clinical evidence regarding the use of Mild wIR-A Hyperthermia in Systemic Sclerosis (SS) and RP highlights the following:

• *Raynaud’s Phenomenon Treatment:* Specialized studies have demonstrated that *Infrared-A Mediated Hyperthermia* is effective in directly treating *Scleroderma-Associated Raynaud’s Phenomenon*, a critical component of the disease affecting peripheral circulation [1].
• *Systemic Sclerosis Amelioration:* Mild wIR-A Hyperthermia has been investigated as a treatment for *Systemic Sclerosis* itself, showing therapeutic potential in ameliorating symptoms and manifestations of the disease [3].
• *Controlled Technology:* Application is carried out using *computer-controlled wIR-A Hyperthermia*, which allows for precise and specific heat dosage to achieve optimal effect on affected tissues and microcirculation [2].

Scientific References (E-E-A-T)